Novel PROTAC probes targeting FOSL1 degradation to eliminate head and neck squamous cell carcinoma cancer stem cells

被引:3
作者
Zaman, Shadid U. [1 ]
Pagare, Piyusha P.
Huang, Boshi
Rilee, Grace [1 ]
Ma, Zhikun [1 ]
Zhang, Yan [1 ,2 ]
Li, Jiong [1 ,2 ,3 ]
机构
[1] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Dept Oral & Craniofacial Mol Biol, Richmond, VA 23298 USA
关键词
HNSCC; AP-1; FOSL1; Cancer stem cell; PROTAC; 3-DIMENSIONAL STRUCTURES; RECOGNITION; METASTASIS; AP-1; MOLPROBITY; INHIBITOR; PREVENTS; PROMOTES; OPINION; BINDING;
D O I
10.1016/j.bioorg.2024.107613
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previously, we identified that AP-1 transcription factor FOSL1 is required to maintain cancer stem cells (CSCs) in HNSCC, and an AP-1 inhibitor, T-5224, can eliminate HNSCC CSCs. However, its potency is relatively low, and furthermore, whether T-5224 eradicates CSCs through targeting FOSL1 and whether FOSL1 serves as an effective target for eliminating CSCs in HNSCC, require further validation. We first found that T-5224 can bind to FOSL1 directly. As a proof-of-principle, several cereblon (CRBN)-recruiting PROTACs were designed and synthesized using T-5224 as a warhead for more effective of targeting FOSL1. The top compound can potently degrade FOSL1 in HNSCC, thereby effectively eliminating CSCs to suppress HNSCC tumorigenesis, with around 30 to 100-fold improved potency over T-5224. In summary, our study further validates FOSL1 as an effective target for eliminating CSCs in HNSCC and suggests that PROTACs may provide a unique molecular tool for the development of novel molecules for targeting FOSL1.
引用
收藏
页数:11
相关论文
共 48 条
[1]   Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 [J].
Aikawa, Yukihiko ;
Morimoto, Kimiko ;
Yamamoto, Tetsuya ;
Chaki, Hisaaki ;
Hashiramoto, Akira ;
Narita, Hirokazu ;
Hirono, Shuichi ;
Shiozawa, Shunichi .
NATURE BIOTECHNOLOGY, 2008, 26 (07) :817-823
[2]  
Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61
[3]  
[Anonymous], 2014, PHARM MED, V28, P195, DOI [10.1007/s40290-014-0064-4, DOI 10.1007/s40290-014-0064-4]
[4]   Head and neck cancer: Current challenges and future perspectives [J].
Bhat, Gh. Rasool ;
Hyole, Rosalie G. ;
Li, Jiong .
ADVANCES IN CANCER RESEARCH, VOL 152, 2021, 152 :67-102
[5]   Opinion - Migrating cancer stem cells - an integrated concept of malignant tumour progression [J].
Brabletz, T ;
Jung, A ;
Spaderna, S ;
Hlubek, F ;
Kirchner, T .
NATURE REVIEWS CANCER, 2005, 5 (09) :744-749
[6]   GENOTYPING OF 73 UM-SCC HEAD AND NECK SQUAMOUS CELL CARCINOMA CELL LINES [J].
Brenner, J. Chad ;
Graham, Martin P. ;
Kumar, Bhavna ;
Saunders, Lindsay M. ;
Kupfer, Robbi ;
Lyons, Robert H. ;
Bradford, Carol R. ;
Carey, Thomas E. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2010, 32 (04) :417-426
[7]  
Chamberlain Philip P, 2019, Drug Discov Today Technol, V31, P29, DOI 10.1016/j.ddtec.2019.02.004
[8]   Preclinical models in head and neck squamous cell carcinoma [J].
Chaves, Patricia ;
Garrido, Maria ;
Oliver, Javier ;
Perez-Ruiz, Elisabeth ;
Barragan, Isabel ;
Rueda-Dominguez, Antonio .
BRITISH JOURNAL OF CANCER, 2023, 128 (10) :1819-1827
[9]   Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma [J].
Chen, Demeng ;
Wu, Mansi ;
Li, Yang ;
Chang, Insoon ;
Yuan, Quan ;
Ekimyan-Salvo, Mari ;
Deng, Peng ;
Yu, Bo ;
Yu, Yongxin ;
Dong, Jiaqiang ;
Szymanski, John M. ;
Ramadoss, Sivakumar ;
Li, Jiong ;
Wang, Cun-Yu .
CELL STEM CELL, 2017, 20 (05) :621-+
[10]   MolProbity: all-atom structure validation for macromolecular crystallography [J].
Chen, Vincent B. ;
Arendall, W. Bryan, III ;
Headd, Jeffrey J. ;
Keedy, Daniel A. ;
Immormino, Robert M. ;
Kapral, Gary J. ;
Murray, Laura W. ;
Richardson, Jane S. ;
Richardson, David C. .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 :12-21